Joan Rou-En Choo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joan Rou-En Choo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Ean Chee
Department of Hematology-Oncology, National University Cancer Institute, Singapore
1 shared publication - Gloria Chan
Department of Haematology-Oncology, National University Cancer Institute, Singapore
1 shared publication - Gokula K. Ramachandran
Cancer Science Institute of Singapore, National University of Singapore, Singapore
1 shared publication Jonathan Wei Jie Lee
Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital, Singapore
1 shared publication- Raghav Sundar
Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut
1 shared publication Robert John Walsh
Department of Haematology-Oncology, National University Cancer Institute, Singapore
1 shared publication
Latest Publications
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
Pilot Study of Gemcitabine, Nab-Paclitaxel, and Ciprofloxacin in Patients With Advanced Pancreatic Ductal Adenocarcinoma
PURPOSE: Gemcitabine-based chemotherapy is standard for metastatic pancreatic ductal adenocarcinoma (PDAC), but resistance limits its efficacy. Bacteria in the PDAC tumor microenvironment may contribute to resistance. Hence, the coadministration of an antibiotic to chemotherapy may potentiate antitumor drug responses. This study evaluates the safety and efficacy of adding ciprofloxacin to gemcitabine-based chemotherapy. Secondary aims included stool microbiome and exhaled breath volatile analysis. MATERIALS AND METHODS: This single-arm study at the National University Cancer Institute, Singapore, enrolled patients with treatment-naïve advanced PDAC. Patients received nab-paclitaxel (125 mg/m 2 ) and gemcitabine (1,000 mg/m 2 ) administered weekly on days 1, 8, and 15 of each 4-week cycle, together with oral ciprofloxacin (500 mg twice daily) until disease progression or intolerable toxicity. Stool and tumor samples were subjected to 16S rRNA sequencing. Primary end points were response rate and safety. Secondary end points included progression-free survival (PFS), overall survival (OS), and microbiome changes. RESULTS: From March 2019 to February 2021, 8 patients were recruited. Best response was stable disease in 5 (62.5%) patients, and 3 patients had progressive disease (PD). The median PFS and OS were 4.3 and 15.4 months, respectively. Two patients developed grade 4 neutropenia and one had grade 3 febrile neutropenia. A total of 50% of patients developed grade 1/2 rash. No additional toxicities from ciprofloxacin were observed. PD correlated with increased Gammaproteobacteria and decreased cytidine deaminase functional potential. Response to therapy was associated with baseline increased abundances of Firmicutes species. CONCLUSION: Gemcitabine-based chemotherapy plus ciprofloxacin demonstrated clinical activity and an acceptable safety profile in PDAC. Lack of response to treatment was associated with increased abundances of Gammaproteobacteria .
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
Pilot Study of Gemcitabine, Nab-Paclitaxel, and Ciprofloxacin in Patients With Advanced Pancreatic Ductal Adenocarcinoma
PURPOSE: Gemcitabine-based chemotherapy is standard for metastatic pancreatic ductal adenocarcinoma (PDAC), but resistance limits its efficacy. Bacteria in the PDAC tumor microenvironment may contribute to resistance. Hence, the coadministration of an antibiotic to chemotherapy may potentiate antitumor drug responses. This study evaluates the safety and efficacy of adding ciprofloxacin to gemcitabine-based chemotherapy. Secondary aims included stool microbiome and exhaled breath volatile analysis. MATERIALS AND METHODS: This single-arm study at the National University Cancer Institute, Singapore, enrolled patients with treatment-naïve advanced PDAC. Patients received nab-paclitaxel (125 mg/m 2 ) and gemcitabine (1,000 mg/m 2 ) administered weekly on days 1, 8, and 15 of each 4-week cycle, together with oral ciprofloxacin (500 mg twice daily) until disease progression or intolerable toxicity. Stool and tumor samples were subjected to 16S rRNA sequencing. Primary end points were response rate and safety. Secondary end points included progression-free survival (PFS), overall survival (OS), and microbiome changes. RESULTS: From March 2019 to February 2021, 8 patients were recruited. Best response was stable disease in 5 (62.5%) patients, and 3 patients had progressive disease (PD). The median PFS and OS were 4.3 and 15.4 months, respectively. Two patients developed grade 4 neutropenia and one had grade 3 febrile neutropenia. A total of 50% of patients developed grade 1/2 rash. No additional toxicities from ciprofloxacin were observed. PD correlated with increased Gammaproteobacteria and decreased cytidine deaminase functional potential. Response to therapy was associated with baseline increased abundances of Firmicutes species. CONCLUSION: Gemcitabine-based chemotherapy plus ciprofloxacin demonstrated clinical activity and an acceptable safety profile in PDAC. Lack of response to treatment was associated with increased abundances of Gammaproteobacteria .